Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

Curr Opin Urol. 2020 Jul;30(4):617-619. doi: 10.1097/MOU.0000000000000777.

Authors

Edmond M Kwan^{1

2}, Arun A Azad^{3

4}

Affiliations

¹ Department of Medicine, School of Clinical Sciences, Monash University.
² Department of Medical Oncology, Monash Health.
³ Department of Medical Oncology, Peter MacCallum Cancer Centre.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

PMID: 32452996
DOI: 10.1097/MOU.0000000000000777

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intravenous
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Docetaxel / therapeutic use*
Humans
Male
Neoplasm Metastasis / drug therapy*
Prostatic Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Docetaxel